CYTO: Auris Medical P/S Multiple
Demand for targeted drug delivery to the brain and auditory system is driving the recruitment of specialized experts at Altamira Therapeutics (CYTO). The price-to-sales valuation exhibits volatility, while 4.40 shows the value of this parameter. Growth prospects are based on OligoPhore patents for cancer treatment, although slow product rollouts and competition in nasal agents limit the business's defensive moats.
Metric breakdowns and analytics for Altamira Therapeutics (CYTO)
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Altamira Therapeutics|CYTO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio altamiratherapeutics.com|CYTO - Company Aggregate Debts|Debts to Net Assets Auris Medical|CYTO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Altamira Therapeutics|Quick Ratio altamiratherapeutics.com
- financial results and valuation multiples details:
CYTO - Net Income|Expected Net Income Altamira Therapeutics|CYTO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio altamiratherapeutics.com|CYTO - PEG Multiple|Business Value to Operating Income Before Depreciation Auris Medical|CYTO - Operating profit EBITDA|Net earnings per one share for the last twelve months Altamira Therapeutics|CYTO - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months altamiratherapeutics.com|CYTO - Earnings growth in current year|Earnings growth forecast for next year Altamira Therapeutics
- sales revenue and business income indicators:
General company analysis:CYTO, Altamira Therapeutics Ltd
The P/S multiple determines the market value of a business per unit of generated revenue, allowing for an assessment of the premium paid for an asset relative to its actual sales. By analyzing the price-to-sales ratio dynamics, an investor compares the valuation of Altamira Therapeutics (CYTO) with the efficiency of its ESG-oriented RNA therapy developments and the transparency of its clinical processes to avoid purchasing an overvalued asset.
Competitors of Altamira Therapeutics
HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|P/S Multiple Verona Pharma PLC VRNA|MENS - Price-to-Revenue Ratio|LGND: Price-to-Revenue Ratio|AMRX (Amneal Pharmaceuticals) - Market Cap to Revenue|PRGO: Market Cap to Sales Volume|ALVO (Alvotech SA) - P/S Multiple|P/S Multiple Liquidia Corp|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|Market Cap to Revenue ANI Pharmaceuticals Corp ANIP|P/S Multiple MNKD (MannKind Corporation)|Price-to-Revenue Coefficient amphastar.com (AMPH)|PCRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S Multiple|Aquestive Corp (AQST) - P/S Multiple|Market Cap to Revenue SCPH|TECX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue TNXP (Tonix Pharmaceuticals Holding Corp.)|Market Cap to Sales Volume SXTC|P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Market Capitalization-to-Revenue Ratio BHST|eXoZymes Inc - P/S Multiple|Price to Sales Oramed Pharmaceuticals|enterabio.com (ENTX) - Price-to-Revenue Ratio|MindWalk Holdings, Inc. - Market Capitalization-to-Revenue Ratio|ABVC (ABVC BioPharma Inc) - P/S Multiple|P/S Multiple Cumberland Corp|Price-to-Revenue Ratio Quantum BioPharma Ltd (QNTM)|FGEN: Price-to-Sales Ratio|P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Price to Sales|SNYR: Market Cap to Revenue|RLYB - P/S Multiple|LEXX (lexariabioscience.com) - Market Cap to Revenue|PULM: Market Cap to Sales Volume|PTHL (Pheton Holdings Limited) - P/S Multiple|Aptorum (APM) - Price-to-Revenue Coefficient|P/S Multiple LYRA|Market Cap to Revenue Impact BioMedical, Inc. IBO|Price-to-Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|Price-to-Revenue Coefficient cbdMD Inc. (YCBD)|PainReform - P/S Multiple|Lipella Pharmaceuticals Inc (LIPO) - Market Cap to Revenue|OPTN (Optinose) - Market Cap to Revenue|Price to Sales Pieris Pharma (PIRS)|Market Cap to Revenue PROC|PTPI (petrospharma.com) - Market Cap to Sales Volume|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN - Price to Sales|Price-to-Revenue Ratio TFF Pharma TFFP
